Create Free Account

By creating account you will get access to hot stocks & personalised emails

Starpharma Holdings Ltd

Healthcare AU SPL

0.096AUD
0.001(1.05%)

Last update at 2024-07-26T02:46:00Z

Day Range

0.100.10
LowHigh

52 Week Range

0.090.33
LowHigh

Fundamentals

  • Previous Close 0.10
  • Market Cap39.18M
  • Volume76592
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-8.18200M
  • Revenue TTM10.52M
  • Revenue Per Share TTM0.03
  • Gross Profit TTM -8.15100M
  • Diluted EPS TTM-0.02

Financials

Income Statement

Balancesheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2023-06-30 2022-06-30 2021-06-30 2020-06-30 2019-06-30
Type yearly yearly yearly yearly yearly
Date 2023-06-30 2022-06-30 2021-06-30 2020-06-30 2019-06-30
Income before tax -15.63800M -16.15400M -19.73200M -14.67800M -14.25400M
Minority interest - - - - -
Net income -15.63800M -16.15400M -19.73200M -14.67800M -12.88700M
Selling general administrative 3.77M 3.29M 4.02M 2.67M 2.50M
Selling and marketing expenses - - - - -
Gross profit 1.82M 1.91M 1.01M 5.14M 1.40M
Reconciled depreciation 1.19M 1.08M 0.93M 0.91M 0.30M
Ebit -18.23600M -17.71200M -22.35500M -16.67100M -15.62100M
Ebitda -17.04200M -16.63400M -21.42100M -15.76000M -15.32300M
Depreciation and amortization 1.19M 1.08M 0.93M 0.91M 0.30M
Non operating income net other - - - - -
Operating income -15.77300M -16.15400M -19.73200M -14.67800M -15.62100M
Other operating expenses 19.85M 21.32M 23.22M 21.79M 17.27M
Interest expense - 0.22M 0.00000M 0.00000M 0.00000M
Tax provision 0.00000M 0.00000M 0.00000M 0.00000M 0.00000M
Interest income 1.27M 0.22M 0.35M 0.52M 1.06M
Net interest income 1.27M 0.22M 0.35M 0.52M 1.06M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense -2.46300M -1.29500M -1.28700M -1.43400M -1.36700M
Total revenue 2.94M 4.68M 1.80M 6.03M 1.65M
Total operating expenses 20.05M 19.62M 23.36M 21.81M 17.02M
Cost of revenue 1.12M 2.78M 0.79M 0.89M 0.25M
Total other income expense net 0.14M 0.26M 1.34M 0.56M 1.37M
Discontinued operations - - - - -
Net income from continuing ops -15.63800M -16.15400M -19.73200M -14.67800M -14.25400M
Net income applicable to common shares -15.63800M -16.15400M -19.73200M -14.67800M -14.25400M
Preferred stock and other adjustments - - - - -
Breakdown 2023-06-30 2022-06-30 2021-06-30 2020-06-30 2019-06-30
Type yearly yearly yearly yearly yearly
Date 2023-06-30 2022-06-30 2021-06-30 2020-06-30 2019-06-30
Total assets 52.09M 66.17M 73.24M 39.08M 48.86M
Intangible assets - - - - -
Earning assets - - - - -
Other current assets 0.93M 0.08M 0.10M 0.04M 0.08M
Total liab 17.27M 17.78M 10.94M 7.75M 6.46M
Total stockholder equity 34.81M 48.39M 62.30M 31.33M 42.40M
Deferred long term liab - - - - -
Other current liab 2.33M 2.31M 2.61M 1.26M 1.88M
Common stock 240.72M 240.67M 240.63M 193.66M 193.62M
Capital stock 240.72M 240.67M 240.63M 193.66M 193.62M
Retained earnings -234.19900M -218.56100M -202.40700M -182.67500M -168.00100M
Other liab 0.05M 0.06M 0.03M 0.09M 0.04M
Good will - - - - -
Other assets - - - - -
Cash 35.18M 49.92M 60.50M 30.05M 41.25M
Cash and equivalents 33.52M 45.79M 57.30M 25.98M 38.31M
Total current liabilities 14.47M 10.23M 10.43M 6.70M 6.43M
Current deferred revenue 0.00300M 0.47M 0.41M 0.44M 0.43M
Net debt -26.90800M -41.72900M -59.33300M -28.48000M -41.22500M
Short term debt 5.52M 0.69M 0.69M 0.60M 0.03M
Short long term debt 4.78M - - - -
Short long term debt total 8.27M 8.19M 1.17M 1.57M 0.03M
Other stockholder equity -6.51600M -22.10800M -38.22300M -10.98600M 16.77M
Property plant equipment 4.96M 5.52M 2.48M 2.40M 1.05M
Total current assets 47.12M 60.66M 70.75M 36.68M 47.81M
Long term investments - - - - -
Net tangible assets 34.81M 48.39M 62.30M 31.33M 42.40M
Short term investments - - - - -
Net receivables 8.23M 7.84M 8.44M 6.09M 6.08M
Long term debt 0.00000M 4.00M - - -
Inventory 2.77M 2.82M 1.72M 0.49M 0.40M
Accounts payable 6.62M 6.76M 6.71M 4.39M 4.10M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income 28.30M 26.29M 24.08M 20.34M 16.77M
Additional paid in capital - - - - -
Common stock total equity - - - 193.66M 193.62M
Preferred stock total equity - - - - -
Retained earnings total equity - - - - -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other -4.96400M -5.51700M -2.48300M -2.40200M 1.05M
Deferred long term asset charges - - - - -
Non current assets total 4.96M 5.52M 2.48M 2.40M 1.05M
Capital lease obligations 3.49M 4.19M 1.17M 1.57M 0.03M
Long term debt total 2.75M 7.49M 0.47M 0.97M 0.00000M
Breakdown 2023-06-30 2022-06-30 2021-06-30 2020-06-30 2019-06-30
Type yearly yearly yearly yearly yearly
Date 2023-06-30 2022-06-30 2021-06-30 2020-06-30 2019-06-30
Investments -0.61000M -0.83600M -0.24600M -0.12500M 0.00800M
Change to liabilities -0.54700M 0.34M 2.91M -0.43600M 1.16M
Total cashflows from investing activities -0.61000M -0.83600M -0.24600M -0.12500M -0.30600M
Net borrowings -0.69500M 3.23M -0.62800M -0.58400M -0.02600M
Total cash from financing activities -0.69500M 3.23M 46.30M -0.58400M -0.02600M
Change to operating activities 0.71M -0.00900M 0.14M 0.17M 0.12M
Net income -15.63800M -16.15400M -19.73200M -14.67800M -14.25400M
Change in cash -14.73800M -10.58200M 30.45M -11.19700M -10.06800M
Begin period cash flow 49.92M 60.50M 30.05M 41.25M 51.32M
End period cash flow 35.18M 49.92M 60.50M 30.05M 41.25M
Total cash from operating activities -13.53300M -13.16200M -14.80800M -10.77600M -10.34400M
Issuance of capital stock - - 48.86M - -
Depreciation 1.19M 1.08M 0.94M 0.91M 0.30M
Other cashflows from investing activities 0.01M 0.00100M 0.00000M 0.00000M 0.00800M
Dividends paid - - 46.30M - -
Change to inventory 0.05M -1.10300M -1.22700M -0.09500M -0.39900M
Change to account receivables -1.25700M 0.63M -2.36900M 0.03M -0.02300M
Sale purchase of stock - 0.00000M -1.93100M -1.93100M -
Other cashflows from financing activities -0.69500M 7.23M 46.30M -0.58400M -0.02600M
Change to netincome 1.95M 2.05M 4.54M 3.32M 2.76M
Capital expenditures 0.62M 0.84M 0.25M 0.12M 0.31M
Change receivables - - - - -
Cash flows other operating - - - - -
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - - -
Change in working capital -1.04200M -0.14000M -0.55100M -0.32500M -0.42200M
Stock based compensation 2.06M 2.25M 3.74M 3.60M 3.37M
Other non cash items 5.63M 4.40M 7.07M 5.65M 3.61M
Free cash flow -14.15400M -13.99900M -15.05400M -10.90100M -10.65800M

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (AUD) Price (AUD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
SPL
Starpharma Holdings Ltd		 0.001 1.05% 0.10 - 312.50 5.29 1.61 2.94 -2.6618
CSL
CSL Ltd		 3.35 1.09% 308.88 41.15 31.35 9.60 5.16 10.91 34.93
TLX
Telix Pharmaceuticals Ltd		 0.10 0.49% 19.32 983.00 21.01 8.47 28.69 8.21 177.65
NEU
Neuren Pharmaceuticals Ltd		 0.35 1.74% 20.45 16.75 38.46 11.63 13.15 10.65 12.39
CU6
Clarity Pharmaceuticals Ltd		 0.04 0.63% 6.34 - - 85.90 15.59 - -18.7407

Reports Covered

Stock Research & News

View All

Profile

Starpharma Holdings Limited, a biopharmaceutical company, engages in the research, development, and commercialization of dendrimer products for pharmaceutical, life-science, and other applications worldwide. The company offers VivaGel BV, a non-antibiotic vaginal gel for the treatment of bacterial vaginosis and prevention of recurrent BV; VIRALEZE, an antiviral nasal spray; and VivaGel condom, an antiviral condom. It is also involved in the development of DEP cabazitaxel that is in Phase 2 clinical trial for the treatment of prostate and other cancers, DEP docetaxel that is in Phase 2 clinical trials for the treatment of colorectal and other cancers, DEP irinotecan that is in Phase 2 clinical trials f for the treatment of pancreatic and other cancers; and EP gemcitabine, DEP HER-2 ADC, and DEP HER-2 radiotherapy completed preclinical trials for the treatment of solid cancers. In addition, the company's DEP radiotheranostics development pipeline includes DEP HER2-zirconium, a HER2-targeted radio diagnostic for HER2-positive cancers, such as breast and gastric cancer; and HER2-targeted DEP SN38 ADC, a targeted ADC therapeutic for the treatment of human ovarian cancer. Starpharma Holdings Limited was incorporated in 1997 and is headquartered in Abbotsford, Australia.

Starpharma Holdings Ltd

4-6 Southampton Crescent, Abbotsford, VIC, Australia, 3067

Key Executives

Name Title Year Born
Dr. Jacinth K. Fairley B.Sc., B.V.Sc.(Hons), GAICD, MBA CEO, MD & Exec. Director 1963
Mr. Nigel J. Baade B.Com, Grad. Dip., CPA CFO & Company Sec. NA
Mr. Justin Cahill CFO & Company Secretary NA
Ms. Cheryl Maley B.Sc., M.B.A. CEO, MD & Director 1969
Mr. Justin Cahill CFO & Company Secretary NA
Ms. Cheryl Maley B.Sc., M.B.A. CEO, MD & Director 1969
Mr. Justin Cahill CFO & Company Secretary NA
Ms. Cheryl Maley B.Sc., M.B.A. CEO, MD & Director 1969
Mr. Justin Cahill CFO & Company Secretary NA
Ms. Cheryl Maley B.Sc., M.B.A. CEO, MD & Director 1969

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.

Our Company

Useful Links

Contact Us

ISO Certified Market Research

Kalkine Solutions Private Limited, authorized representative of Kalkine Pty Ltd, holds ISO 27001:2022 certification bearing Certificate No.- IC-IS-2404072

Our Company

Useful Links

Contact Us

Disclaimer

The information given by Kalkine Pty Ltd ABN34 154 808 312 (Australian Financial Services License Number 425376) on this website is general information or advice only.

It does not take into account any of your personal objectives, circumstances or needs. Choosing an investment is an important decision. If you do not feel confident making a decision based on the recommendations Kalkine has made in our reports, you should consider obtaining personal advice from an authorised adviser.

There may be a product disclosure statement or other offer document for the securities and financial products we write about in Kalkine Reports. You should obtain a copy of the product disclosure statement or offer document before making any decision about whether to acquire the security or product. Terms & Conditions have been provided for our services, please go through them and also read our Financial Services Guide.

Our website may contain information on past performance of particular investments. Past performance is not an indicator of future performance. Hypothetical returns may not reflect actual performance. Any displays of potential investment opportunities are for sample purposes only and may not actually be available to investors.

The information on the website does not constitute an offer to sell securities or a solicitation of an offer to buy securities. Our reports contain general recommendations to invest in securities.

Copyright 2024 Krish Capital Pty. Ltd. All rights reserved. No part of this website, or its content, may be reproduced in any form without our prior consent.